Oncology Peer Review On-The-Go: Impact of Treatment Refusal on Survival for Small Cell Lung Cancer

Podcast

The latest episode of the podcast dissects a piece of original research from the Journal ONCOLOGY focusing on the impact of treatment refusal on patients with small cell lung cancer.

In this episode, CancerNetwork® examines an article from the March issue of the Journal ONCOLOGY® titled “Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer.” The original research article found that treatment refusal among patients with small cell lung cancer was associated with worse survival, and strategies to increase patient acceptance of recommended treatment need to be studied further. We spoke with one of the study authors, K.M. Monirul Islam, MD, PhD, of the Georgia Medical Center, to learn more about this research.

For the response perspective, we spoke with Jennifer W. Carlisle, MD, an assistant professor of hematology and medical oncology at Winship Cancer Institute of Emory University. Carlisle spoke about small cell lung cancer, how treatment refusal impacts treatment of a patient, and more.

Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Recent Videos
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.
The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).
Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.
Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
Related Content
In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Delving Into the Current State of Clinical Practice in SCLC

Roman Fabbricatore
December 3rd 2025
Article

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Patients with ES-SCLC who had an ECOG performance status of 2 or 3 achieved ORRs of 52.4% and 45.5%, respectively, with the study treatment.

Durvalumab/Carboplatin/Etoposide Proves Tolerable in ES-SCLC

Tim Cortese
November 19th 2025
Article

Patients with ES-SCLC who had an ECOG performance status of 2 or 3 achieved ORRs of 52.4% and 45.5%, respectively, with the study treatment.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Combinations of anti-angiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis

Tim Cortese
October 31st 2025
Article

Combinations of antiangiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

Russ Conroy
October 25th 2025
Article

Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.